Long-Term outcomes after liver transplantation among human immunodeficiency virus-infected recipients

Transplantation

Volumn 100, Issue 1, 2016, Pages 141-146

  Locke, Jayme E ^a   Durand, Christine ^b   Reed, Rhiannon D ^a   MacLennan, Paul A ^a   Mehta, Shikha ^a   Massie, Allan ^c   Nellore, Anoma ^a   DuBay, Derek ^a   Segev, Dorry L ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; UNITED STATES; ADVERSE EFFECTS; COMPLICATION; END STAGE LIVER DISEASE; HIV INFECTIONS; HIV SURVIVOR; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY;

COINFECTION; END STAGE LIVER DISEASE; FEMALE; GRAFT SURVIVAL; HEPATITIS C; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84952334357     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000829     Document Type: Conference Paper

References (21)

1. HIV in the United States. A Glance 2013 [June 9, 2014]. Available from: http://www.cdc.gov/hiv/statistics/basics/ataglance.html.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860.
3. Rao TK. Human immunodeficiency virus infection in end-stage renal disease patients. Semin Dial. 2003;16:233-244.
4. Blumberg EA, Stock P; Practice ASTIDCo. Solid organ transplantation in the HIV-infected patient. Am J Transplant. 2009;(9 Suppl 4):S131-S135.
5. Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation. 2007;84:563-571.
6. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716-726.
7. de Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant. 2006;6:2983-2993.
8. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47: 407-417.
9. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1-And 3-year outcomes. Am J Transplant. 2008;8: 355-365.
10. Cooper C, Rollet-Kurhajec K, Young J, et al. HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-Treated HIV/hepatitis C virus-coinfected patients. HIV Med. 2015;16:24-31.
11. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-2593.
12. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440-2447.
13. Swinnen LJ. Outcomes of kidney transplantation in HIV-infected recipients. N Engl JMed. 2011;364:683.
14. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009;9:1946-1952.
15. Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: Analysis of United Network for Organ Sharing database. Transplantation. 2008;85:359-368.
16. Ragni MV, Eghtesad B, Schlesinger KW, et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005;11:1425-1430.
17. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology. 2010;138:159-164.
18. Kamath PS, Wiesner RH, MalinchocM, et al. Amodel to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464-470.
19. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol. 2008;48: 353-367.
20. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002;36:202-210.
21. GratM, Kornasiewicz O, Lewandowski Z, et al. Post-Transplant outcomes of patients with and without hepatitis C virus infection according to donor age and gender matching. Ann Transplant. 2013;18:705-715.